These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26938782)

  • 1. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.
    Leenen CH; Goverde A; de Bekker-Grob EW; Wagner A; van Lier MG; Spaander MC; Bruno MJ; Tops CM; van den Ouweland AM; Dubbink HJ; Kuipers EJ; Dinjens WN; van Leerdam ME; Steyerberg EW
    Genet Med; 2016 Oct; 18(10):966-73. PubMed ID: 26938782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age.
    Goverde A; Spaander MC; van Doorn HC; Dubbink HJ; van den Ouweland AM; Tops CM; Kooi SG; de Waard J; Hoedemaeker RF; Bruno MJ; Hofstra RM; de Bekker-Grob EW; Dinjens WN; Steyerberg EW; Wagner A;
    Gynecol Oncol; 2016 Dec; 143(3):453-459. PubMed ID: 27789085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
    Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
    PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
    J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.
    Erten MZ; Fernandez LP; Ng HK; McKinnon WC; Heald B; Koliba CJ; Greenblatt MS
    Dig Dis Sci; 2016 Oct; 61(10):2887-2895. PubMed ID: 27384051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
    Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
    Health Technol Assess; 2014 Sep; 18(58):1-406. PubMed ID: 25244061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.
    Sie AS; Mensenkamp AR; Adang EMM; Ligtenberg MJL; Hoogerbrugge N
    Ann Oncol; 2014 Oct; 25(10):2001-2007. PubMed ID: 25081898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
    Ladabaum U; Wang G; Terdiman J; Blanco A; Kuppermann M; Boland CR; Ford J; Elkin E; Phillips KA
    Ann Intern Med; 2011 Jul; 155(2):69-79. PubMed ID: 21768580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learnt from the implementation of a colorectal cancer screening programme for lynch syndrome in a tertiary public hospital.
    Dueñas N; Navarro M; Sanjuán X; Ruiz N; Iglesias S; Matias-Guiu X; Guardiola J; Kreisler E; Biondo S; González S; Legido R; Blanco A; Navarro S; Asiain L; Santos C; Capellá G; Pineda M; Brunet J
    Cancer Epidemiol; 2023 Feb; 82():102291. PubMed ID: 36410089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing strategies to reduce morbidity and mortality from Lynch syndrome.
    Keränen A; Ghazi S; Carlson J; Papadogiannakis N; Lagerstedt-Robinson K; Lindblom A
    Scand J Gastroenterol; 2018 Dec; 53(12):1535-1540. PubMed ID: 30572730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
    Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
    Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.